Acute Myelogenous Leukemia (AML) Due to Therapy

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Acute Myelogenous Leukemia (AML) Due to Therapy trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

All recent trials (2 shown)

Active — Not RecruitingPhase 2

NCT04231851

CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute M…

This is a phase 2 single-arm, open-label clinical trial determining efficacy of CPX-351 in combination with Glasdegib in subjects with Acute Myelogenous Leukemi…

United States30 participantsStarted 2020-02-19

Treatment: Glasdegib, CPX-351

CompletedPhase 3

NCT00006348

Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment

RATIONALE: Antiemetic drugs, such as ondansetron, may help to reduce or prevent nausea and vomiting in patients with advanced cancer. PURPOSE: This randomized…

United States100 participantsStarted 2000-10

Treatment: ondansetron, placebo